Completed Infection & Immunity Heart, Stroke & Blood

How does aberrant innate immune activation damage the microvasculature of the brain?

In plain English

AI plain-English summary

In lupus and Aicardi-Goutières syndrome, the body’s own immune system attacks the tiny blood vessels that feed the brain. These chronic autoimmune disorders cause severe neurological damage in both children and adults, yet no treatments exist for the brain symptoms. The problem is that doctors know a specific immune alarm signal—type I interferon—is overactive in these patients, but they do not understand exactly how it damages the brain’s microvasculature. This project will use genetically engineered mice that mimic human interferon dysregulation, alongside data from patients with neurolupus, to pinpoint which cells and molecules in the brain’s small blood vessels are targeted by interferon. The researchers also want to know whether different subtypes of interferon cause different types of damage, and how this process unfolds in a lupus model where interferon activation occurs spontaneously. This is fundamental science. It will not produce a drug tomorrow. But by identifying the precise immune pathways that drive brain damage in lupus and related disorders, it could reveal specific molecular targets for future therapies. Similar fundamental work on interferon pathways has already led to treatments for multiple sclerosis and certain rare inflammatory diseases—a deeper understanding here could eventually do the same for the neurological devastation of lupus.

View original technical description
Systemic lupus erythematosus and Aicardi-Goutières syndrome are chronic autoimmune disorders which can affect the brain of adults and children. Despite their high disease burden, there is no effective treatment for the neurological manifestations of these conditions, highlighting the need to identify defined immune pathways which drive brain damage. These diseases are characterised by aberrant activation of the type I interferon response and we have shown this pathway can damage small blood vessels of the brain. However the cellular and molecular mechanisms by which this occurs are unknown. In this proposal we will develop mouse models of interferon dysregulation, linked to human experimental medicine studies of "interferonopathic" diseases such as neurolupus. Our overarching aim is to understand the role of this pathophysiological axis in mediating brain disease in disorders such as lupus, with a view to developing therapeutic interventions. Goal 1. To determine the cellular and molecular targets of type I interferon within the brain’s microvasculature. Goal 2. To identify the influence of type I interferon subtype on microvascular disease Goal 3. To understand how microvascular disease arises in a lupus model of spontaneous interferon activation

View the original record at the funder ↗

Researchers

David Hunt (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Activation of the type 1 interferon response by nucleic acids: A fundamental mechanism causing human neuroinflammatory disease.
Cellular drivers of type I interferon-mediated neuropathology
Microglia and type I interferon: protective and pathogenic mechanisms
Elucidating monocyte-specific disease mechanisms in systemic lupus erythematosus
Regulation of type I and II interferon in CD180 regulated B cells and their role in Lupus pathogenesis

Original classification

Senior Research Fellowship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.